合成肽 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
=== Blood loss === Red blood cells contain iron, so blood loss also leads to iron loss. There are several causes of blood loss, including menstrual bleeding, gastrointestinal bleeding, stomach ulcers, and bleeding disorders. The bleeding may occur quickly or slowly. Slow, chronic blood loss within the body – such as from a peptic ulcer, angiodysplasia, inflammatory bowel disease, a colon polyp or gastrointestinal cancer (e.g., colon cancer) – can cause iron-deficiency anemia.
=== Activation by thrombospondin-1 === Thrombospondin-1 (TSP-1) is a matricellular glycoprotein found in plasma of healthy patients with levels in the range of 50–250 ng/ml. TSP-1 levels are known to increase in response to injury and during development. TSP-1 activates latent TGF-beta by forming direct interactions with the latent TGF-β complex and induces a conformational rearrangement preventing it from binding to the matured TGF-β.
The publication of medical abbreviations for use in the journals published by the American Medical Association is dictated by the AMA Manual of Style is the style guide of the American Medical Association. Periods are generally not used. Plurals for medical acronyms are represented by affixes a lowercase s with no apostrophe. Arrows may also be used to indicate elevation (↑), diminution (↓), and causation (→, ←).
A second controversial aspect of the award was that eight months before Banting's and Best's paper, the Romanian physiologist Nicolae Paulescu had reported the discovery of a pancreas extract that he dubbed pancrein, which lowered blood glucose concentration. Banting and Best even cited him in their paper, but misinterpreted his findings, purportedly because of an error in translation from French. Best publicly apologized for that mistake many years later.
Factor X, or Stuart-Prower factor, followed, in 1956. This protein was identified in a Ms. Audrey Prower of London, who had a lifelong bleeding tendency. In 1957, an American group identified the same factor in a Mr. Rufus Stuart. Factors XI and XIII were identified in 1953 and 1961, respectively. The view that the coagulation process is a "cascade" or "waterfall" was enunciated almost simultaneously by MacFarlane in the UK and by Davie and Ratnoff in the US, respectively.
Sources: en.wikipedia.org
=== Research === He started his research in the chemistry of natural products. At Washington State University he established early steps in the metabolism of d-neomethyl-α-D-glucoside in pipermint (Mentha piperita) rhizomes via in vivo studies. Bhushan developed a de novo method for direct resolution of certain racemates by liquid chromatography. Later, the approach was applied for direct enantioseparation of several active pharmaceutical ingredients (APIs). It is now an established approach in literature. 1994 onwards, the method was extended to such resolutions by ligand exchange principle. The method is of significant importance to pharmaceutical industry and analytical laboratories associated with regulatory agencies for determination and control of enantiomeric purity (and isolation of native enantiomers) of a variety of APIs since many of them are marketed and administered as racemic mixture while only one enantiomer is therapeutically useful. Bhushan supervised the Ph.D. theses of > 30 scholars and has published more than 270 research papers.
1 At the state elections on 15 February 1936, James Kenneally lost his East Perth seat to an Independent Labor candidate, Thomas Hughes. Kenneally and another candidate contested the poll citing Hughes's status as an undischarged bankrupt at the time of the poll (meaning that he was not eligible to stand), and a fresh by-election was called for 9 May, which Hughes won. On 13 May, Kenneally resigned from the Collier Ministry. Bert Hawke replaced him in the Executive Council and in two of his portfolios, whilst Millington and Wise reshuffled portfolios, in part to unite Works and Water Supplies under one minister. 2 Willcock assumed all of Collier's portfolios from 20 August 1936 until 27 August 1936 whilst Caucus selected a new Cabinet.
=== Promotions === Pre-purchasing of the Windows version on Steam began on September 11, 2007. Those who pre-purchased via this method received a ten-percent discount and were able to play the Team Fortress 2 beta starting on September 17, 2007. The original PC version of The Orange Box came with Peggle Extreme, a ten-level playable demo of Peggle Deluxe, which contained levels with graphical themes of games contained in The Orange Box. However Peggle Extreme was later made free to download for anyone with a Steam account and is not included in the current PC version of the Orange Box on Steam. Half-Life 2: Lost Coast is also technically included with the PC version of The Orange Box, as it was offered as a free download to all owners of Half-Life 2. And as of 2024 is listed as a part of the Orange Box after Lost Coast and Half-Life 2 Episodes One, and Two were integrated into Half-Life 2 as a part of its 20th anniversary update. The same is true for Half-Life 2: Deathmatch, which is now included with Half-Life 2 following Half-Life 2's 20th anniversary update.
Graves' disease is an autoimmune disorder that is the most common cause of hyperthyroidism. In Graves' disease, for an unknown reason autoantibodies develop against the thyroid stimulating hormone receptor. These antibodies activate the receptor, leading to development of a goitre and symptoms of hyperthyroidism, such as heat intolerance, weight loss, diarrhoea and palpitations. Occasionally such antibodies block but do not activate the receptor, leading to symptoms associated with hypothyroidism. In addition, gradual protrusion of the eyes may occur, called Graves' ophthalmopathy, as may swelling of the front of the shins. Graves' disease can be diagnosed by the presence of pathognomonic features such as involvement of the eyes and shins, or isolation of autoantibodies, or by results of a radiolabelled uptake scan. Graves' disease is treated with anti-thyroid drugs such as propylthiouracil, which decrease the production of thyroid hormones, but hold a high rate of relapse. If there is no involvement of the eyes, then use of radioactive isotopes to ablate the gland may be considered. Surgical removal of the gland with subsequent thyroid hormone replacement may be considered, however this will not control symptoms associated with the eye or skin.
Sources: en.wikipedia.org
=== Fundamental Materials Science === Quantum dots can also be used to study fundamental effects in materials science. By coupling two or more such quantum dots, an artificial molecule can be made, exhibiting hybridization even at room temperature. Precise assembly of quantum dots can form superlattices that act as artificial solid-state materials that exhibit unique optical and electronic properties.
=== Legal categorization and legal issues in a near future === Currently, siRNAs are chemically synthesized and are therefore legally categorized in the EU and the US as simple medicinal products. But as bioengineered siRNA (BERAs) are in development, these would be classified as biological medicinal products, at least in the EU. The development of the BERAs technology raises the question of the categorization of drugs having the same mechanism of action but being produced chemically or biologically. This lack of consistency should be addressed.
It is divided between its east and west coasts by the Titiwangsa Mountains, rising to a peak elevation of 2,183 metres (7,162 ft) at Mount Korbu, part of a series of mountain ranges running down the centre of the peninsula. These mountains are heavily forested, and mainly composed of granite and other igneous rocks. Much of it has been eroded, creating a karst landscape. The range is the origin of some of Peninsular Malaysia's river systems. The coastal plains surrounding the peninsula reach a maximum width of 50 kilometres (31 mi), and the peninsula's coastline is nearly 1,931 km (1,200 mi) long, although harbours are only available on the western side.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.